FEDERAL BUREAU OF INVESTIGATION
FOI/PA
DELETED PAGE INFORMATION SHEET
FOI/PA# 1468056-000

Total Deleted Page(s) = 16
Page 7 ~ Duplicate;
Page 8 ~ Duplicate;
Page 9 ~ Duplicate;
Page 10 ~ Duplicate;
Page 25 ~ Duplicate;
Page 26 ~ Duplicate;
Page 32 ~ Duplicate;
Page 33 ~ Duplicate;
Page 34 ~ Duplicate;
Page 35 ~ Duplicate;
Page 41 ~ Duplicate;
Page 46 ~ Duplicate;
Page 47 ~ Duplicate;
Page 48 ~ Duplicate;
Page 52 ~ Duplicate;
Page 53 ~ Duplicate;

XXXXXXXXXXXXXXXXXXXXXXXX
X Deleted Page(s) X
X No Duplication Fee X
X For this Page X
XXXXXXXXXXXXXXXXXXXXXXXX

 b6 b7C

[redacted] b6 b7C

that was dated October 26, 1989, in which the author threatened to tamper with SANDOZ' products.

[redacted] advised that he did in fact write this letter as well as the unsigned letter that was dated October 20, 1989. b6 b7C

[redacted] advised that he was shocked when SA [redacted] showed him the two letters the previous day when he was interviewed. [redacted] advised that the words in the two letters did not actually register with him even though they were his words. [redacted] advised for that reason he denied writing these letters when he was interviewed by SA [redacted] the previous day. b6 b7C

[redacted] advised that although he wrote these letters it was because he was under such severe stress and career problems that he did not appreciate the consequences of his act. b6 b7C

[redacted] advised that he never meant to threaten the SANDOZ products and he never intended on tampering with any SANDOZ products. b6 b7C

[redacted] was specifically asked if any SANDOZ products have been tampered with and he advised that no products have been tampered with and again stated that he never intended to tamper with the products or to actually threaten the products. b6 b7C

[redacted] advised that he was sorry for having caused all this trouble but has now realized the seriousness of his act and that he would never do anything like this again. b6 b7C

)-36 (Rev. 8-29-85)

FBI

TRANSMIT VIA:
- ☐ Teletype
- ☐ Facsimile
- ☐ _____

PRECEDENCE:
- ☐ Immediate
- ☐ Priority
- ☐ Routine

CLASSIFICATION:
- ☐ TOP SECRET
- ☐ SECRET
- ☐ CONFIDENTIAL
- ☐ UNCLAS E F T O
- ☐ UNCLAS

Date _____

^PAGE TWO, NK 250-NK-64202, UNCLAS

TO [redacted] AND DATED 10/24/89. b6 b7C

THIS LETTER WAS UNSIGNED AND EXPRESSED DISSATISFACTION WITH THE MANAGEMENT AND LEADERSHIP OF SANDOZ CORP AS WELL AS THE NEW PARKING REGULATIONS THAT WERE TO BE IMPLIMENTED.

THIS LETTER STATED THAT AN ADMINSTRATIVE SLOW DOWN WOULD GO INTO EFFECT IN THE TECHNICAL OPERATIONS SECTION AND "ALSO STARTING NOVEMBER, ONE BATCH OF GOODS PER MONTH WILL LEAVE THE PLANT WITH DEFECTS, MINOR AT FIRST AND MORE SERIOUS LATER. ALL SUCH BATCHES WILL HAVE TO BE RECALLED. YOU AND THE F.D.A. WILL BE INFORMED WHICH PRODUCTS AND BATCHES AFTER THEY HAVE LEFT DISTRIBUTION (HOPEFULLY NOT TOO LATE)".

[redacted] MADE AVAILABLE THE ORIGINAL THREATENING LETTER AS WELL AS A LIST OF POTENTIAL SUSPECTS, AND OTHER SANDOZ DOCUMENTS. [redacted] ADVISED THAT HE HAS ALSO NOTIFIED THE LOCAL OFFICE OF THE F.D.A. b6 b7C

ON 10/30/89 [redacted] b6 b7C

[redacted], SANDOZ CORP., ONE RIDGEDALE AVENUE, EAST HANOVER, NEW JERSEY, WAS AGGRESSIVELY INTERVIEWED BY A BUREAU AGENT IN REGARD TO HIS KNOWLEDGE OF THE THREATENING LETTER. [redacted]

Approved: _____ Transmitted _____ (Number) (Time) Per _____

FILER FILENAME _____

MRI/J _____ INS _____

ACC. AT _____

)-36 (Rev. 8-29-85)

FBI

TRANSMIT VIA:
- ☐ Teletype
- ☐ Facsimile
- ☐ _____

PRECEDENCE:
- ☐ Immediate
- ☐ Priority
- ☐ Routine

CLASSIFICATION:
- ☐ TOP SECRET
- ☐ SECRET
- ☐ CONFIDENTIAL
- ☐ UNCLAS E F T O
- ☐ UNCLAS

Date _____

1 ^PAGE THREE, NK 250-NK-64202, UNCLAS
2 DENIED ANT SPECIFIC KNOWLEDGE OF THE LETTER AND DENIED WRITING
3 THE LETTER. [redacted] WAS ADVISED THAT THE THREATENING LETTER b6 b7C
4 SAMPLER OF HIS KNOWN WRITING AS WELL AS BE EXAMINED FOR HIS
5 FINGERPRINTS. [redacted] AGAIN DENIED WRITING THE THREATENING
6 LETTER OR TAMPERING WITH CONSUMER PRODUCTS.
7 ON 10/31/89 [redacted] RECONTACTED THE BUREAU AGENT THAT b6 b7C
8 INTERVIEWED HIM ON 10/30/89 AND REQUESTED THAT HE BE RE-
9 INTERVIEWED. ON 10/31/89, [redacted] WAS RE-INTERVIEWED AND
10 DURING THIS INTERVIEW PROVIDED AT FULL CONFESSION AND ADMITTED
11 WRITING THE THREATENING LETTER. [redacted] ADVISED THAT NO SANDOZ
12 PRODUCTS HAS BEEN TAMPERED WITH AND HE NEVER INTENDED TO TAMPER. b6 b7C
13 [redacted]
14
15
16 ON 10/31/89, AUSA [redacted] NEWARK, NEW JERSEY, WAS
17 ADVISED OF THE CONTENTS OF THE THREATENING LETTER AS THE
18 INTERVIEW OF [redacted] AND AUSA [redacted] THEREAFTER DECLINED FEDERAL b6 b7C
19 PROSECUTION OF [redacted]
20 [redacted]
21

Approved: _____ Transmitted _____ Per _____
(Number) (Time)

FILER FILENAME _____

MRI/J _____ INS _____

ACC. AT _____

)-36 (Rev. 8-29-85)

FBI

TRANSMIT VIA:
- ☐ Teletype
- ☐ Facsimile
- ☐ _____

PRECEDENCE:
- ☐ Immediate
- ☐ Priority
- ☐ Routine

CLASSIFICATION:
- ☐ TOP SECRET
- ☐ SECRET
- ☐ CONFIDENTIAL
- ☐ UNCLAS E F T O
- ☐ UNCLAS

Date _____

^PAGE FOUR, NK 250-NK-64202, UNCLAS

ON 10/31/89, SUPERVISOR [redacted] F.D.A. EAST ORANGE, NEW JERSEY, WAS ADVISED OF THE ABOVE INFORMATION AND THE OPINION OF AUSA [redacted] b6 b7C

CAPTIONED SUBJECT IS DESCRIBED AS FOLLOWS:

[redacted] b6 b7C

NEWARK DIVISION AT WEST PATERSON, NEW JERSEY: WILL CONFIRM OPINION OF AUSA [redacted] b6 b7C

BT

Approved: _____ Transmitted _____ (Number) (Time) Per _____

FILER FILENAME _____

MRI/J _____ INS _____

ACC. AT _____

FD-340a (Rev. 10-3-77)

(Title) 250-NK-64202-1A

(File No.)

Item	Date Filed	To be returned Yes	To be returned No		Disposition
1	1/24/90			[redacted] DATE RECEIVED: 10/30/89. BY: [redacted]	
2	1/24/90			[redacted] DATE RECEIVED: 10/30-31/89. BY: [redacted]	
3.	1/9/91			FD-192 RECEIVED 12/6/90 FROM [redacted] BY SEE 1B1	

b6
b7C

250-NK-64202-

[redacted]

b6
b7C

[redacted]

FD-340 (Rev. 4-2-85)

Field File No. 250- NK- 64202-1A1

Serial # of Originating Document _____

OO and File No. _____

Date Received 10/30/89

From _____
(Name of Contributor)

_____
(Address of Contributor)

B [redacted] b6 b7C
(Name of Special Agent)

To Be Returned ☐ Yes ☑ No Receipt Given ☐ Yes ☑ No

Grand Jury Material - Disseminate Only Pursuant to Rule 6(e), Federal Rules of Criminal Procedure ☐ Yes ☐ No

Title:

Reference: _____
(Communication Enclosing Material)

Description: [redacted] b6 b7C

[redacted]

10/30/89

[redacted]

b6
b7C

[redacted]

b6
b7C

[redacted]

10/30/89 [redacted] Sorry to

b6
b7C

[redacted]

Rec'd letter in ~~[illegible]~~ entire office mail - Mrs opened it & read it:

MR. [redacted]

b6
b7C

[redacted]

10/30/89 Rec'd letter + envelope from MENTOR TRUCKS Box 1[illegible] TO FBI.

10/26/89 - Also rec'd a copy of a letter dated 9/20/89 addressed to [redacted] b6 b7C

[redacted] send me copy.

10/26/89 ACGK [redacted] b6 b7C

[redacted]

b6
b7C

b6
b7C

FD-340 (Rev. 4-2-85)

250- NK-64202-1A2

Field File No. _____

Serial # of Originating Document _____

OO and File No. _____

Date Received 10/30-31/88

From _____
(Name of Contributor)

_____
(Address of Contributor)

_____

By [redacted] b6 b7C

To Be Returned ☐ Yes ☒ No Receipt Given ☐ Yes ☒ No

Grand Jury Material - Disseminate Only Pursuant to Rule 6(e), Federal Rules of Criminal Procedure ☐ Yes ☐ No

Title:

Reference: _____
(Communication Enclosing Material)

Description: ☐ Original notes re interview of [redacted] b6 b7C

10/30/89

b6
b7C

b6
b7C

b6
b7C

THURS-Nov 10/26/89

b6
b7C

b6
b7C

[redacted]

b6
b7C

He did not mention the tampering

He said there was going to be a meeting about the letter @ Stops

[redacted]

b6
b7C

[redacted]

Over my opinion they are trustworthy,

[redacted]

b6
b7C

b6
b7C

b6
b7C

b6
b7C

10/31/89

[redacted]

b6
b7C

(1) Trust FBI
(2) Under Cross

[redacted]

(3)
(4)
(5)

[redacted]

b6
b7C

[redacted]

Cross checked when I saw the new letters yesterday. The words did not register although they were new.

Never was meant to threaten people or tamper with people. Have not tampered with anything.

FD-340 (Rev. 4-2-85)

Field File No. 250-NK-64202-1A3

Serial # of Originating Document _____

OO and File No. _____

Date Received 12/6/90

From [redacted]

b6
b7C

(Address of Contributor)

(City and State)

By Det 1B1

(Name of Special Agent)

To Be Returned ☐ Yes ☒ No Receipt Given ☐ Yes ☒ No

Grand Jury Material - Disseminate Only Pursuant to Rule 6(e), Federal Rules of Criminal Procedure ☐ Yes ☒ No

Title: FD-192

Reference: _____

(Communication Enclosing Material)

Description: ~~☐ Original notes re interview~~ of FD-192

Bulky Exhibit - Inventory of Property Acquired as Evidence
FD-192 (Rev. 7-18-85)

Date 11/1/89

Title and Character of Case

[redacted]

SANDOZ PHARMACEUTICALS CORP.
EAST HANOVER, N.J. - VICTIM
T.C.D.
(OO: NK)

b6
b7C

Date Property Acquired	Source From Which Property Acquired	
10/30/89	[redacted]	[redacted] SANDOZ CORP. EAST HANOVER N.J.

b6
b7C

Location of Property or Bulky Exhibit	Reason for Retention of Property and Efforts Made to Dispose of Same
BULKY #3	EVIDENCE

To Be Returned	See Serial	Agent Submitting Property or Exhibit	Agent Assigned Case
☐ Yes ☒ No		SA [redacted]	SA [redacted]

b6
b7C

☐ Yes ☒ No Grand Jury Property - Disseminate Only Pursuant to Rule 6(e), Federal Rules of Criminal Procedure.

☐ Yes ☒ No Property to be Forfeited to the Government

Description of Property or Exhibit

1. ORIGINAL WHITE ENVELOPE BEARING THE TYPEWRITTEN NAMES [redacted]
2. ORIGINAL TYPEWRITTEN LETTER DATED 10/24/89 ADDRESSED TO [redacted]
3. ORIGINAL TYPEWRITTEN LETTER DATED 10/20/89 ADDRESSED TO [redacted]
4. ORIGINAL SANDOZ MAILING ENVELOPE
5. ORIGINAL FEDERAL EXPRESS MAILING ENVELOPE.

b6
b7C

b6
b7C

b6
b7C

For Valuable and/or Narcotics Evidence Only

Evidence Bag Seal # _____

Signature of Two Special Agents Verifying and Sealing Bag Contents _____

SEMIANNUAL INVENTORY CERTIFICATION TO JUSTIFY RETENTION OF PROPERTY (Initial and Date)

250-NK-64202-1B1

BLOCK STAMP

SEARCHED [redacted]
SERIALIZED [redacted]
NOV 01 1989
FBI — NEWARK

b6
b7C

Field File # 250-NK-64202-1B1

OO: NEWARK

EVIDENCE (PACKAGE COPY)

CHAIN OF CUSTODY

b6
b7C

Accepted Custody	Date	Time	Released Custody	Date	Time
Signature [redacted] Reason [redacted]	10/30/89	11:00 AM	[redacted] TOT MULLIN	11/89	4:30 PM
Signature [redacted] Reason Storck	11/1/99	4:30pm	TOT [redacted]	11/6/90	1:15PM
Signature [redacted] Reason [redacted]	12/6/90	1:00 PM			
Signature Reason					
Signature Reason					
Signature Reason					
Signature Reason					
Signature Reason					
Signature Reason					
Signature Reason					

b6
b7C

Item No. **Remarks**

250-NK-64202-2

NOV 08 1988
NJ — NEWARK

b6
b7C

FD-302 (REV. 3-10-82)

FEDERAL BUREAU OF INVESTIGATION

1

Date of transcription 11/9/89

On October 30, 1989, [redacted] SANDOZ PHARMACEUTICALS, Route 10, East Hanover, New Jersey (NJ), made available via FEDERAL EXPRESS Overnight Letter, the following original documents: b6 b7C

1. Original white envelope bearing the typewritten name, [redacted] b6 b7C

2. Original typewritten letter dated October 24, 1989, addressed to [redacted]

3. Original typewritten letter, dated October 20, 1989, addressed to [redacted] b6 b7C

[redacted] advised that the above described items, number one and two, were received on October 26, 1989, by [redacted], SANDOZ PHARMACEUTICALS CORPORATION. [redacted] advised that items one and two were received via the SANDOZ CORPORATION intra-office mail. b6 b7C

[redacted] advised that item number three was received four days earlier and it appears that it possibly was written by the same unknown person. b6 b7C

Copies of the above described documents are attached hereto:

Investigation on 10/30/89 at West Paterson, New Jersey File # Newark 250-NK-64202

by SA [redacted] Date dictated 11/6/89 b6 b7C

This document contains neither recommendations nor conclusions of the FBI. It is the property of the FBI and is loaned to your agency; it and its contents are not to be distributed outside your agency.

b6
b7C

[redacted] 10/24/89 b6 b7C

[redacted] (the incompetent, arrogant) and [redacted] (the clown) have to go. We have had enough. "Playing games" is no substitute for competent leadership. We will also not accept the new parking regulations: you certainly seem to be an expert at killing the little motivation that still remains.

In order to give you time to act we have decided on the following:

an administrative go-slow will go into effect in Tech. Ops in November. Our estimates are that the company will start having stockouts by about January.

also starting in November 1 batch of goods per month will leave the plant with defects, minor at first and more serious later. All such batches will have to be recalled. You and the FDA will be informed which products and batches after they have left distribution (hopefully not to late).

You have several options:

do as we request
fire all Tech. Ops. staff above the hourly-worker level
ignore this warning (at your peril)

Good luck with the crisis task-force meetings. No one will talk as everyone concerned is, at this time, very dissolutioned with the so called "upper management".

Copy to Max Link on 11/1/89

[redacted] 10/21/89 10/30/89 [redacted] b6 b7C

[redacted]

b6
b7C

Although you probably don't realize it your credibility with your direct reports is virtually zero! Although they continue to display a cooperative approach and have refrained so far from public negative comments their sentiments are well known. At the last count 5 were actively seeking positions outside the company: of course it's always the best who leave first.

Your credibility with your indirect reports - those at the Director, SBU(?) and down to the Manager level; the people who carry out the day to day business of implementing policies, plans and all the actions so vital to producing results - is below zero and continuing to diminish.

The above mentioned problem has been the subject of discussion by many staff in various areas for several weeks now. As many are still basically dedicated to the company's future and wellbeing we have decided to write you this note: it's even possible you're not aware of the impending crisis.

The main problem is your managerial style which virtually everyone finds shockingly inappropriate - especially for someone who is still an outsider, doesn't really know what's going on and seems to be making little effort to understand the company culture. You cannot change this culture overnight - although most would agree there is room for massive improvement.

This is not Basle! You will not get the results Basle, you and we want and need if you continue on your current course. We suggest you learn to listen and solicit opinions - BEFORE you issue EDICTS. Do you recall the 'stony silence' which greeted your decisions and comments at the recent Marketing Meeting? Perhaps you didn't even notice.

We have good products and some outstanding people (e.g. [redacted] etc. We also have some real dummies (e.g. [redacted]) who seem to be condoned for whatever reason?? (being [redacted] golf partner is hardly a qualification for promotion to a senior position - or is it?). Picking names for promotion 'out of a hat' (e.g. [redacted] defies all logic. Who is doing the picking - [redacted]? Some of us are convinced she has far too much influence. You would do well to develop participative relationships with more of your staff. This won't happen if [redacted] is allowed to continue her arrogant-doorkeeper practices.

b6
b7C

b6
b7C

Serious trouble is also apparently brewing in Tech. Ops. Line staff will no longer put up with [redacted]s technical incompetence and intimidating style. Passive resistance or even strike action cannot be discounted. Are you aware?

We hope we have your attention. You will have our continued support if we see change. If not, there is always a higher authority.

The above comments are harsh, yes, but the intention is to help you help us - with your leadership - take Sandoz to the top. Together we can do it. Alone you cannot. DON'T LET US, OR SANDOZ, DOWN.

10/20/89

U.S. Department of Justice

Federal Bureau of Investigation

In Reply, Please Refer to
File No. 250-NK-64202

Post Office Box 660
West Paterson, New Jersey 07424
November 16, 1989

Honorable Samuel A. Alito, Jr.
United States Attorney
Room 502, Federal Building
970 Broad Street
Newark, New Jersey 07101

Attention: Mr. [redacted]
Assistant United States Attorney

b6
b7C

Re: [redacted]
Sandoz Pharmaceutical
Corporation
East Hanover, New Jersey -
Victim;
Tampering with Consumer
Products

Dear [redacted]

This will confirm a conversation on October 31, 1989, between Assistant United States Attorney (AUSA) [redacted] of your office and Special Agent (SA) [redacted], of the Federal Bureau of Investigation.

b6
b7C

At that time AUSA [redacted] was advised that on October 26, 1989, [redacted] Sandoz Pharmaceuticals Corporation, East Hanover, New Jersey, received via the Sandoz interoffice mail an envelope containing a one page typewritten letter addressed to [redacted] that was dated October 24, 1989.

b6
b7C

AUSA [redacted] was advised that this letter was unsigned and expressed dissatisfaction with the management and leadership of the Sandoz Corporation as well as the new parking regulations that were to be implemented at Sandoz.

b6
b7C

Enclosure-1
2-Addressee
2-Newark (250-NK-64202)

[redacted]

250-NK-64202-3

b6
b7C

[redacted]

[redacted]

AUSA [redacted] was advised that this letter stated in essence that an administrative slow down would go into effect in the technical operations section and "also starting in November, one batch of goods per month will leave the plant with defects, minor at first and more serious later. All such batches will have to be recalled. You and the FDA will be informed which products and batches after they have left distribution (hopefully not too late)." b6 b7C

AUSA [redacted] was advised that on October 30, 1989, [redacted] at the Sandoz Corporation in East Hanover, New Jersey, was interviewed by SA [redacted] in regards to this threatening letter and at that time [redacted] denied any knowledge of the contents of the letter and specifically denied writing this letter. b6 b7C

AUSA [redacted] was further advised that on October 31, 1989, [redacted] recontacted SA [redacted] and requested that SA [redacted] reinterview [redacted] in regard to the threatening letter. b6 b7C

AUSA [redacted] was advised that on October 31, 1989, [redacted] was reinterviewed and during this interview provided a full confession and admitted writing the threatening letter to the Sandoz Corporation. [redacted] stated that no Sandoz products have been tampered with and he never intended to tamper. [redacted] b6 b7C

On October 31, 1989, AUSA [redacted] thereafter declined federal prosecution of [redacted] b6 b7C

In view of the opinion of AUSA [redacted] no further investigation will be conducted in this matter by the Federal Bureau of Investigation. b6 b7C

Very truly yours,

Gary Penrith
Acting Special Agent in Charge

By: [redacted] b6 b7C
Supervisory Special Agent

250-NK-64202-4

SEARCHED
SERIALIZED
FILED

1990

FBI — NEWARK

b6
b7C

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 11/9/89

[redacted]

SANDOZ PHARMACEUTICAL CORPORATION, Route ten, East Hanover, New Jersey, advised that on October 26, 1989, [redacted] who is the Personal Secretary to [redacted] SANDOZ PHARMACEUTICAL CORPORATION, received via the SANDOZ intraoffice mail an envelope containing a one page typewritten letter addressed to [redacted] and that was dated October 24, 1989: b6 b7C

[redacted] advised that this letter was unsigned and in essence expressed dissatisfaction with the management and leadership of SANDOZ CORPORATION as well as the new parking regulations that were to be implemented. b6 b7C

[redacted] advised that this letter stated that an administrative slow down would go into effect in the technical operations section and "also starting November, one batch of goods per month will leave the plant with defects, minor at first and more serious later. All such batches will have to be recalled. You and the Food and Drug Administration (FDA) will be informed which products and batches after they have left distribution (hopefully not too late)." [redacted] made available the original threatening letter, the mailing envelope as well as a list of potential suspects and other SANDOZ documents. [redacted] advised that he has also notified the local office of the FDA. b6 b7C b6 b7C

Investigation on 10/30/89 at East Hanover, New Jersey File # Newark 250-NK-64202

by SA [redacted] Date dictated 11/3/89 b6 b7C

This document contains neither recommendations nor conclusions of the FBI. It is the property of the FBI and is loaned to your agency; it and its contents are not to be distributed outside your agency.

250-NK-64202-5

SEARCHED GEN
SERIALIZ
FILED

b6
b7C

FD-302 (REV. 3-10-82)

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 11/9/89

[redacted] SANDOZ CORPORATION, One Ridgedale Avenue, East Hanover, New Jersey, was contacted at his place of employment and was advised that he was to be interviewed in regards to any knowledge that he had regarding a threatening letter that had been sent to [redacted] of the SANDOZ PHARMACEUTICAL CORPORATION: b6 b7C

[redacted] advised that as of this time he has not personally seen this threatening letter, and he has no personal knowledge of its contents but he did advise that on Thursday, October 26, 1989, [redacted] at SANDOZ, called WATTERTON to his office and told [redacted] had received a letter. b6 b7C

[redacted] advised that [redacted] told him that this letter had some comments about [redacted] as well as [redacted] also advised that [redacted] told him that the letter mentioned the parking regulations that were to be implemented at SANDOZ. [redacted] advised that [redacted] did not mention anything to him that the letter threatened to tamper with the SANDOZ products. [redacted] advised that [redacted] told him that there would be a meeting later in the day regarding the letter. b6 b7C

[redacted] advised that [redacted] asked him for his, [redacted] opinion as to who might have written such a letter. [redacted] advised that he told [redacted] he had no knowledge as to who would have written this letter, and he denied writing the letter himself. [redacted] advised that he suggested that [redacted] start some kind of dialogue with [redacted] advised that in his opinion these individuals are trustworthy and generally have an idea as to what is going on in the SANDOZ CORPORATION, as well as the feelings of some of the SANDOZ employees. b6 b7C

Investigation on 10/30/89 at East Hanover, New Jersey File # Newark 250-NK-64202

by SA [redacted] Date dictated 11/3/89 b6 b7C

This document contains neither recommendations nor conclusions of the FBI. It is the property of the FBI and is loaned to your agency; it and its contents are not to be distributed outside your agency.

b6
b7C

[redacted] advised that on Friday, October 27, 1989, [redacted] who works in quality assurance, called another meeting at approximately 9:30 A.M. [redacted] advised that among those attending this meeting were himself, [redacted] advised that [redacted] told those in attendance that there was a threatening letter and that [redacted] if there was a threat of tampering or if there was actual tampering with the SANDOZ products.

b6
b7C

[redacted] advised that [redacted] told those in attendance that there was no evidence that any products had been tampered with.

b6
b7C

[redacted] advised that as of the end of that meeting, he still had not seen the actual letter and did not know what it said.

At this point in the interview, [redacted] was displayed a copy of the threatening letter that was sent to [redacted] read the contents of this letter and advised that he had never seen this letter before. [redacted] was specifically asked if he wrote this letter, and he denied writing the letter. [redacted] was also asked if he knew who wrote this letter, and [redacted] again advised that he knew nothing about the letter and had no idea who would have sent it to [redacted]

b6
b7C

[redacted] was also displayed another letter that was sent to [redacted] and that was unsigned and that was dated October 20, 1989. [redacted] read this letter and denied any knowledge of this letter and specifically denied that he wrote this letter.

b6
b7C

[redacted] was then displayed a confidential typewritten memorandum dated September 15, 1989, that bore his typewritten name as the author. [redacted] advised that he did in fact write this confidential memorandum.

b6
b7C

[redacted] was specifically advised that all of the above documents including the one that he admitted writing bore the dates in the lower left hand corner. [redacted] again denied writing the threatening letter as well as the unsigned letter dated October 20, 1989.

b6
b7C

b6
b7C

[redacted] was specifically advised that the threatening letter that was sent to [redacted] on October 26, 1989, as well as the unsigned letter dated October 20, 1989, would be sent to the Federal Bureau of Investigation laboratory to be examined for fingerprints. [redacted] advised that his fingerprints would not be on these documents as he never saw them before and had no knowledge about them.

b6
b7C

[redacted] advised that if he should learn any additional information as to the writer of this letter he would immediately contact the Federal Bureau of Investigation.

b6
b7C

The following information was obtained through observation and interview:

Name:
Sex:
Race:
Date of Birth:
Place of Birth:
Social Security
Account Number:
Height:
Weight:
Hair:
Eyes:
Home Address:

Home Telephone
Number:

[redacted]

b6
b7C

250-NK-64202-6

SEARCHED
SERIALIZED
FILED

FOI

1990

b6
b7C

FD-302 (REV. 3-10-82)

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 11/13/89

[redacted] SANDOZ PHARMACEUTICAL CORPORATION, One Ridgedale Avenue, East Hanover, New Jersey, contacted Special Agent (SA) [redacted], who was currently at the SANDOZ PHARMACEUTICAL CORPORATION and advised that he, [redacted] had some additional information in regard to the investigation that SA [redacted] was conducting pertaining to a threatening letter that was sent to [redacted] at SANDOZ PHARMACEUTICAL CORPORATION. [redacted] requested to meet with SA [redacted] at SANDOZ PHARMACEUTICAL CORPORATION: b6 b7C

[redacted] was then interviewed in a conference room at the SANDOZ PHARMACEUTICAL CORPORATION at which time [redacted] stated that he had thought about the interview with SA [redacted] the previous day, in which he denied writing a threatening letter to the chairman of the board. b6 b7C

[redacted] stated that he had prepared some notes regarding this incident and requested that he be allowed to read them. b6 b7C

SA [redacted] advised [redacted] that he could read his notes and that SA [redacted] would be interested in hearing anything that [redacted] had to say. b6 b7C

[redacted] then referring to his handwritten notes stated that he trusted the integrity of the Federal Bureau of Investigation (FBI) and knew that their investigation would be thorough in regards to this threatening letter. [redacted] advised that he, [redacted] b6 b7C

Investigation on 10/31/89 at East Hanover, New Jersey File # Newark 250-NK-64202

by SA [redacted] Date dictated 11/6/89 b6 b7C

This document contains neither recommendations nor conclusions of the FBI. It is the property of the FBI and is loaned to your agency; it and its contents are not to be distributed outside your agency.

)-36 (Rev. 8-29-85)

FBI

TRANSMIT VIA:
- [x] Teletype
- [ ] Facsimile
- [ ] _____

PRECEDENCE:
- [ ] Immediate
- [x] Priority
- [ ] Routine

CLASSIFICATION:
- [ ] TOP SECRET
- [ ] SECRET
- [ ] CONFIDENTIAL
- [ ] UNCLAS E F T O
- [x] UNCLAS

Date 11/2/89

0012

1 FM FBI NEWARK (250-NK-64202) (P)

2 TO DIRECTOR FBI (250-)/PRIORITY/

3 BT

4 UNCLAS

5 CITE: //3510:3413//

6 PASS: FBIHQ, SSA [redacted] VIOLENT CRIMES SECTION. b6 b7C

7

8 SUBJECT: [redacted] SANDOZ PHARMACEUTICALS CORP., EAST

9 HANOVER, NEW JERSEY-VICTIM; T.C.P.; OO: NEWARK.

10 ON 10/30/89, [redacted]

11 [redacted] SANDOZ PHARMACEUTICALS CORP., RT 10 EAST HANOVER, NEW

12 JERSEY, ADVISED THAT ON 10/26/89 [redacted]

13 [redacted] b6 b7C

14 SANDOZ PHARMACEUTICALS CORP., RECEIVED VIA THE INTRA-OFFICE MAIL

15 AN ENVELOPE CONTAINING A ONE PAGE TYPE WRITTEN LETTER ADDRESSED

16 [redacted]

17 250-NK-64202-1

18 SEARCHED [redacted] INDEXED [redacted] b6 b7C

19 SERIALIZED FILED NOV 1989

20 [redacted]

21 [redacted] 00 2/306

Approved: [redacted] Transmitted _____ (Number) _____ (Time) Per _____

FILER FILENAME BBT00250.306

MRI/J 1738/306 INS 14

ACC. AT 2142 2NOV89

FEDERAL BUREAU OF INVESTIGATION
FOI/PA
DELETED PAGE INFORMATION SHEET
FOI/PA# 1468056-000

Total Deleted Page(s) = 83
Page 6 ~ b5; b6; b7C; b7E;
Page 7 ~ b5; b6; b7C; b7E;
Page 8 ~ b5; b6; b7C; b7E;
Page 9 ~ b5; b6; b7C; b7E;
Page 10 ~ b5; b6; b7C; b7E;
Page 11 ~ b5; b6; b7C; b7E;
Page 12 ~ b5; b6; b7C; b7E;
Page 13 ~ b5; b6; b7C; b7E;
Page 14 ~ b5; b6; b7C; b7E;
Page 15 ~ Duplicate;
Page 16 ~ Duplicate;
Page 22 ~ b6; b7C; b7E;
Page 23 ~ b6; b7C; b7E;
Page 24 ~ b6; b7C; b7E;
Page 25 ~ b6; b7C; b7E;
Page 26 ~ b6; b7C; b7E;
Page 27 ~ b6; b7C; b7E;
Page 28 ~ b6; b7C; b7E;
Page 29 ~ b5; b6; b7C; b7E;
Page 30 ~ b5; b6; b7C; b7E;
Page 31 ~ b5; b6; b7C; b7E;
Page 32 ~ b5; b6; b7C; b7E;
Page 33 ~ b5; b6; b7C; b7E;
Page 34 ~ b5; b6; b7C; b7E;
Page 35 ~ b5; b6; b7C; b7E;
Page 36 ~ b5; b6; b7C; b7E;
Page 37 ~ b5; b6; b7C; b7E;
Page 38 ~ b5; b6; b7C; b7E;
Page 39 ~ b5; b6; b7C; b7E;
Page 40 ~ b5; b6; b7C; b7E;
Page 41 ~ b5; b6; b7C; b7E;
Page 42 ~ b5; b6; b7C; b7E;
Page 43 ~ b5; b6; b7C; b7E;
Page 44 ~ b5; b6; b7C; b7E;
Page 45 ~ b5; b6; b7C; b7E;
Page 46 ~ b5; b6; b7C; b7E;
Page 47 ~ b5; b6; b7C; b7E;
Page 48 ~ b5; b6; b7C; b7E;
Page 49 ~ b5; b6; b7C; b7E;
Page 50 ~ b5; b6; b7C; b7E;
Page 51 ~ b5; b6; b7C; b7E;
Page 52 ~ b5; b6; b7C; b7E;
Page 53 ~ b5; b6; b7C; b7E;
Page 54 ~ b5; b6; b7C; b7E;
Page 55 ~ b5; b6; b7C; b7E;
Page 56 ~ b5; b6; b7C; b7E;
Page 57 ~ b5; b6; b7C; b7E;
Page 58 ~ b5; b6; b7C; b7E;
Page 59 ~ b5; b6; b7C; b7E;
Page 60 ~ b5; b6; b7C; b7E;
Page 61 ~ b5; b6; b7C; b7E;
Page 64 ~ Duplicate;
Page 68 ~ b6; b7C; b7E;
Page 69 ~ b6; b7C; b7E;
Page 70 ~ b6; b7C; b7E;
Page 71 ~ b6; b7C; b7E;
Page 72 ~ b6; b7C; b7E;
Page 73 ~ b6; b7C; b7E;
Page 74 ~ b5; b6; b7C; b7E;
Page 77 ~ b5; b6; b7C; b7E;
Page 78 ~ b5; b6; b7C; b7E;
Page 79 ~ b5; b6; b7C; b7E;
Page 80 ~ b5; b6; b7C; b7E;
Page 81 ~ b5; b6; b7C; b7E;
Page 82 ~ b5; b6; b7C; b7E;
Page 83 ~ b5; b6; b7C; b7E;
Page 84 ~ b5; b6; b7C; b7E;

********** -COMM. JOURNAL- ********** DATE OCT-30-2006 *** TIME 16:40 *** P.01

MODE = MEMORY TRANSMISSION START=OCT-30 16:38 END=OCT-30 16:40

FILE NO.= 070

STN NO.	COM	ABBR NO.	STATION NAME/TEL.NO.	PAGES	DURATION
001	OK		[redacted]	006/006	00:01'59"

-FBI BOSTON -

********** -SEVENTH FLOOR - ***** - [redacted] *********

b6
b7C
b7E

FD-448
Revised
10-27-2004

FEDERAL BUREAU OF INVESTIGATION
FACSIMILE COVER SHEET

PRECEDENCE

○ Immediate ○ Priority ◉ Routine

CLASSIFICATION

○ Top Secret ○ Secret ○ Confidential ○ Sensitive ◉ Unclassified

TO

Name of Office: [redacted]
Facsimile Number: [redacted]
Date: 10/30/2006
Attn: [redacted]
Room:
Telephone Number: [redacted]

b6
b7C

FROM

Name of Office: FBI - Boston, MA
Number of Pages: (including cover) 6
Originator's Name: [redacted]
Approved:

b6
b7C

DETAILS

Subject:
Health Insurance Portability & Accountability Actt Subpoena

Special Handling Instructions:
If you have any questions please call AUSA [redacted]

b6
b7C

Brief Description of Communication Faxed:
HIPAA subpoena for records. Deadline: 11/28/2006. Copy will also be forwarded by U.S. Mail to:
[redacted]

b6
b7C

WARNING

Information attached to the cover sheet is U.S. Government Property. If you are not the intended recipient of this information disclosure, reproduction, distribution, or use of this information is prohibited (18.USC, § 641). Please notify the originator or local FBI Office immediately to arrange for proper disposition.

(Rev. 01-31-2003)

FEDERAL BUREAU OF INVESTIGATION

Precedence: ROUTINE **Date:** 07/12/2005

To: Boston **Attn:** SSA [redacted] b6 b7C

From: Boston [redacted] b7E

Contact: SA [redacted]

Approved By: [redacted] b6 b7C

Drafted By: [redacted]

Case ID #: 209A-BS-92295-18
209A-BS-92295 Sub-SOP-2

Title: [redacted]

Synopsis: To establish a sub-file which contains all subpoena information pertaining to [redacted] b6 b7C

Details: Subpoenas have been issued by the United States Attorney's office in regard to an investigation pertaining to [redacted] Due to the highly sensitive nature of the materials, it is requested that a sub-file be established for all materials pertaining to [redacted] subpoena information. The sub-file will be titled, 209A-BS-92295 Sub-SOP b6 b7C

♦♦

open sub-file "SOP"
7-13-05

O&A
Sub SOP
[redacted]
7-19-05 b6 b7C

[redacted]

209A-BS-92295-SOP-

[redacted]

(Rev. 01-31-2003)

FEDERAL BUREAU OF INVESTIGATION

Precedence: PRIORITY **Date:** 07/21/2005

To: Newark **Attn:** West Trenton RA

From: Boston [redacted]

Contact: SA [redacted]

Approved By: [redacted]

Drafted By: [redacted]

b6
b7C
b7E

Case ID #: 209A-BS-92295 - 17
209A-BS-92295 Sub-SOP - 1

Title: [redacted]

b6
b7C

Synopsis: To request the assistance of the Newark Division's West Trenton Resident Agency to serve the attached HIPPA subpoena to Sondoz Inc., 506 Carnegie Center, Suite 400, Princeton, New Jersey, 08540. [redacted] will accept service of the subpoena. [redacted] advised that [redacted] would also be able to accept service of the subpoena.

b6
b7C

Administrative: [redacted] Sandoz Inc. [redacted] was contacted telephonically on Wednesday, 7/20/2005, by SA [redacted] and notified of the forthcoming HIPPA subpoena. [redacted] requested that the attached HIPPA subpoena be served in person versus service via fax.

b6
b7C

Enclosure(s):

1. One original HIPPA subpoena with attachment addressed to [redacted]
2. One copy of the original subpoena with attachment addressed to [redacted]

b6
b7C

(Please note that [redacted] was acquired by Sandoz Inc.)

Details: In furtherance of an active Qui'tam investigation into [redacted] the Boston Healthcare Fraud Squad requests the assistance of the Newark Division's West Trenton Resident Agency. It is requested that the enclosed HIPPA subpoena and attachment be served to:

b6
b7C

Assigned
SA [redacted] 7/26/05

Sandoz Inc.
506 Carnegie Center, Suite 400
Princeton, New Jersey 08540

Sondoz Inc., [redacted] has been contacted by the Boston division and will accept delivery of the subpoena. [redacted] advised that [redacted] would also be able to accept service of the subpoena. b6 b7C

LEAD(s):

Set Lead 1: (Action)

NEWARK

AT WEST TRENTON

Please serve the attached subpoena to:

Sandoz Inc.
506 Carnegie Center, Suite 400
Princeton, New Jersey 08540

Sondoz Inc., [redacted] has been contacted by the Boston division and will accept delivery of the subpoena. [redacted] advised that [redacted] would also be able to accept service of the subpoena. b6 b7C

After service has been accepted, please return the original subpoena to, SA [redacted] Boston Division, [redacted] b6 b7C b7E

♦♦

(Rev. 01-31-2003)

FEDERAL BUREAU OF INVESTIGATION

Precedence: ROUTINE **Date:** 07/21/2005

To: Boston **Attn:** SSA [redacted]

From: Boston [redacted]
Contact: SA [redacted]

b6
b7C
b7E

Approved By: [redacted]

Drafted By: [redacted]

Case ID #: 209A-BS-92295 -19
209A-BS-92295 SUB-SOP -3

Title: [redacted]

b6
b7C

Synopsis: To report the service of three HIPPA subpoenas via fax and to report a lead which was sent the West Trenton RA in New Jersey to service a fourth HIPPA subpoena.

Details: Four HIPPA subpoenas have been issued by the United States Attorney's Office in regard to an investigation pertaining to [redacted] On 7/20/2005, three HIPPA subpoena's were serviced via fax to the following:

b6
b7C

[redacted]

b6
b7C

b6
b7C

[redacted]

In addition, a lead has been sent on 7/21/2005 to the Newark Divisions West Trenton Resident Agency to service the fourth HIPPA subpoena to the following:

Sandoz Inc.
506 Carnegie Center, Suite 400
Princeton, NJ 08540

[redacted] b6 b7C

♦♦

(Rev. 01-31-2003)

FEDERAL BUREAU OF INVESTIGATION

Precedence: ROUTINE **Date:** 07/01/2005

To: Boston ✓ **Attn:** SA [redacted]

From: Philadelphia
[redacted]
Contact: SA [redacted]

b6
b7C
b7E

Approved By: [redacted]

Drafted By: [redacted]

Case ID #: 209A-BS-92295 - 14

Title: [redacted]

b6
b7C

Synopsis: Report of service of the attached subpoena to the [redacted]

Details: In furtherance of an active Qui'tam investigation into [redacted] the Philadelphia Health Care Fraud Squad has served the enclosed subpoena and attachment to:

[redacted]

b6
b7C

The subpoena was served on [redacted] the above address on June 30, 2005 at 4:15pm. The Philadelphia Health Care Fraud Squad considers this investigative action complete.

♦♦

209A-BS-92295-SOP-4

UNITED STATES OF AMERICA
DEPARTMENT OF JUSTICE

SUBPOENA DUCES TECUM

TO: [redacted] b6 b7C

YOU ARE HEREBY COMMANDED TO APPEAR BEFORE _____
Assistant United States Attorney [redacted] b6 b7C
an official of the U.S. Department of Justice, and you are hereby required to bring with you and produce the following: See attached

which are necessary in the performance of the responsibility of the U.S. Department of Justice to investigate Federal health care offenses, defined in 18 U.S.C. § 24(a) to mean violations of, or conspiracies to violate: 18 U.S.C. §§669, 1035, 1347, or 1518; and 18 U.S.C. §§ 287, 371, 664, 666, 1001, 1027, 1341, 1343, or 1954 if the violation or conspiracy relates to a health care benefit program (defined in 18 U.S.C. § 24(b)).

PLACE AND TIME FOR APPEARANCE:
United States Attorney's Office, One Courthouse Way, Suite 9200, Boston, MA 02210, on July 22, 2005 at 10 o'clock A.M, or at your option, the documents may be mailed to the Assistant U.S. Attorney listed at:

AUSA [redacted] b6 b7C
U.S. Attorney's Office, 5th Floor
408 Atlantic Avenue (John Williams Coastguard Building)
Boston, MA 02110

if received prior to the date and time for appearance.

Failure to comply with the requirements of this subpoena will render you liable to proceedings in the district court of the United States to enforce obedience to the requirements of this subpoena, and to punish default or disobedience.

Issued under authority of Sec. 248 of the Health Insurance Portability & Accountability Act of 1996, Public Law No. 104-91 (18 U.S.C. § 3486)

IN TESTIMONY WHEREOF

[redacted] b6 b7C
Health Care Fraud Chief, USAO Massachusetts
the undersigned official of the U.S. DEPARTMENT OF JUSTICE, has hereunto set her hand this
13th [redacted]
(SIGNATURE)



FORM CRM-180
MAR. 97

RETURN
OF
SERVICE

I, being a person over 18 years of age, hereby certify that a copy of this subpoena was duly served on the person named herein by means of --

1. personal delivery to an individual, to wit:

[redacted]

(Address)

2. personal delivery to an address, to wit:

_____
(Description of premises)

_____
(Address)

_____

_____

3. registered or certified mailing to:

_____
(Name)

_____
Address)

_____

( ) a.m.
at 4:15 (✓) p.m. on 6-30-05

SA [redacted] Philadelphia Division
(Signature)
600 Arch St, Philadelphia PA 19106

UNITED STATES OF AMERICA
DEPARTMENT OF JUSTICE

SUBPOENA DUCES TECUM

b6
b7C

Upon contumacy or refusal to obey, this subpoena shall be enforceable by order of the appropriate United States District Court.

b6
b7C

(Rev. 08-28-2000)

FEDERAL BUREAU OF INVESTIGATION

Precedence: ROUTINE **Date:** 08/1/2005

To: Boston **Attn:** SA [redacted]

From: Newark
Trenton RA
Contact: SA [redacted]

b6
b7C
b7E

Approved By: [redacted]

Drafted By: [redacted]

Case ID #: ~~209A-BS-92295~~ (Pending) -21
209A-BS-92295 Sub-SOP (Pending) -8

Title: [redacted]

b6
b7C

Synopsis: Subpoena served to SANDOZ, INC. on 7/26/2005.

Reference: 209A-BS-92295 Serial 17

Enclosure(s): Enclosed for BS is an original executed HIPPA subpoena and an original and one copy of an FD-302 documenting service of the subpoena to SANDOZ, INC.

Details: On 7/26/2005, a U.S. Department of Justice Subpoena Duces Tecum was served to [redacted] SANDOZ. INC., 506 Carnegie Center, Suite 400, Princeton, New Jersey 08540, telephone number [redacted]

b6
b7C

[redacted] advised that he would not accept the subpoena since it was addressed to [redacted] It was explained to [redacted] that since SANDOZ, INC. was a subsidiary of [redacted] he could accept the subpoena and if he had any questions about compliance, he could contact the Assistant United States Attorney named on the subpoena. Again, [redacted] refused to accept the subpoena. The subpoena was left at the front reception desk in [redacted] presence.

b6
b7C

♦♦

FD-302 (Rev. 10-6-95)

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 08/1/2005

A U.S. Department of Justice Subpoena Duces Tecum was served to [redacted] SANDOZ. INC., 506 Carnegie Center, Suite 400, Princeton, New Jersey 08540, telephone number [redacted] The subpoena commanded the production of documents, explained on an attachment to the subpoena, to the United States Attorney's Office, Boston, Massachusetts on August 26, 2005. b6 b7C

[redacted] advised that he would not accept the subpoena since it was addressed to [redacted] It was explained to [redacted] that since SANDOZ, INC. was a subsidiary of [redacted] he could accept the subpoena and if he had any questions about compliance, he could contact the Assistant United States Attorney named on the subpoena. Again, [redacted] refused to accept the subpoena. The subpoena was left at the front reception desk in [redacted] presence. b6 b7C

Investigation on 7/26/2005 at Princeton, New Jersey

File # 209A-BS-92295 -20 Date dictated 7/26/2005

by SA [redacted] b6 b7C

This document contains neither recommendations nor conclusions of the FBI. It is the property of the FBI and is loaned to your agency; it and its contents are not to be distributed outside your agency.

209A-BS-92295-SOP-9

b6
b7C

To File:
209A-BS-92295-
SUB SOP

UNITED STATES OF AMERICA
DEPARTMENT OF JUSTICE

SUBPOENA DUCES TECUM

TO: [redacted] b6 b7C

YOU ARE HEREBY COMMANDED TO APPEAR BEFORE _____
Assistant United States Attorney [redacted]
an official of the U.S. Department of Justice, and you are hereby required to bring with you and produce the following: See attached

which are necessary in the performance of the responsibility of the U.S. Department of Justice to investigate Federal health care offenses, defined in 18 U.S.C. § 24(a) to mean violations of, or conspiracies to violate: 18 U.S.C. §§669, 1035, 1347, or 1518; and 18 U.S.C. §§ 287, 371, 664, 666, 1001, 1027, 1341, 1343, or 1954 if the violation or conspiracy relates to a health care benefit program (defined in 18 U.S.C. § 24(b)).

PLACE AND TIME FOR APPEARANCE:
United States Attorney's Office, One Courthouse Way, Suite 9200, Boston, MA 02210, on October 31, 2005 at 10 o'clock A.M, or at your option, the documents may be mailed to the Assistant U.S. Attorney listed at:

AUSAs [redacted] b6 b7C
U.S. Attorney's Office, 5th Floor
408 Atlantic Avenue (John Williams Coastguard Building)
Boston, MA 02110

if received prior to the date and time for appearance.

Failure to comply with the requirements of this subpoena will render you liable to proceedings in the district court of the United States to enforce obedience to the requirements of this subpoena, and to punish default or disobedience.

Issued under authority of Sec. 248 of the Health Insurance Portability & Accountability Act of 1996, Public Law No. 104-91 (18 U.S.C. § 3486)

IN TESTIMONY WHEREOF

[redacted] b6 b7C
Health Care Fraud Chief, USAO Massachusetts
the undersigned official of the U.S. DEPARTMENT OF JUSTICE, has hereunto set her hand this
22nd day of September 2005

[redacted]



FORM CRM-180
MAR. 97

RETURN OF SERVICE

, being a person over 18 years of age, hereby certify that a copy of this subpoena was duly served on the person named herein by means of --

1. personal delivery to ~~an individual~~, to wit:

[redacted]

(Address)

2. personal delivery to an address, to wit:

(Description of premises)

(Address)

3. registered or certified mailing to:

(Name)

Address)

at (X) a.m. -9151

[redacted]

(Signature)

Special Agent, FBI

(Title)

UNITED STATES OF AMERICA
DEPARTMENT OF JUSTICE

b6
b7C

SUBPOENA DUCES TECUM

Upon contumacy or refusal to obey, this subpoena shall be enforceable by order of the appropriate United States District Court.

b6
b7C

(Rev. 01-31-2003)

FEDERAL BUREAU OF INVESTIGATION

Precedence: ROUTINE **Date:** 09/26/2005

To: Boston **Attn:** SSA [redacted]

From: Boston [redacted]
Contact: SA [redacted]

b6
b7C
b7E

Approved By: [redacted]

Drafted By: [redacted]

Case ID #: 209A-BS-92295 - 25
209A-BS-92295 SUB-SOP ✓ - 10

Title: [redacted]

b6
b7C

Synopsis: To report the service of two HIPPA subpoenas via fax.

Details: Two HIPPA subpoenas have been issued by the United States Attorney's Office in regard to an investigation pertaining to [redacted] On 9/26/2005, two HIPPA subpoena's were serviced via fax to the following:

b6
b7C

[redacted]

b6
b7C

209A-BS-92295-SOP-11

To file:
209A-BS-92295
Sub-SOP

(Rev. 01-31-2003)

FEDERAL BUREAU OF INVESTIGATION

Precedence: ROUTINE **Date:** 10/25/2005

To: Boston **Attn:** SSA [redacted]

From: Boston [redacted]

Contact: SA [redacted]

Approved By: [redacted]

Drafted By: [redacted]

Case ID #: 209A-BS-92295 -29
209A-BS-92295 SUB-SOP -12

Title: [redacted]

b6
b7C
b7E

b6
b7C

Synopsis: To report the service of one HIPPA subpoena via fax.

Details: One HIPPA subpoena has been issued by the United States Attorney's Office in regard to an investigation pertaining to [redacted] On 10/25/2005, one HIPPA subpoena was serviced via fax, at 12:27 PM, to the following:

b6
b7C

[redacted]

♦♦

b6
b7C

[redacted]

UNITED STATES OF AMERICA
DEPARTMENT OF JUSTICE

SUBPOENA DUCES TECUM

TO: [redacted] b6 b7C

YOU ARE HEREBY COMMANDED TO APPEAR BEFORE
Assistant United States Attorney [redacted]
an official of the U.S. Department of Justice, and you are hereby required to bring with you and produce the following: See attached

which are necessary in the performance of the responsibility of the U.S. Department of Justice to investigate Federal health care offenses, defined in 18 U.S.C. § 24(a) to mean violations of, or conspiracies to violate: 18 U.S.C. §§669, 1035, 1347, or 1518; and 18 U.S.C. §§ 287, 371, 664, 666, 1001, 1027, 1341, 1343, or 1954 if the violation or conspiracy relates to a health care benefit program (defined in 18 U.S.C. § 24(b)).

PLACE AND TIME FOR APPEARANCE:
United States Attorney's Office, One Courthouse Way, Suite 9200, Boston, MA 02210, on November 28, 2006 at 10 o'clock A.M, or at your option, the documents may be mailed to the Assistant U.S. Attorney listed at:

AUSAs [redacted] b6 b7C
U.S. Attorney's Office, 5th Floor
408 Atlantic Avenue (John Williams Coastguard Building)
Boston, MA 02110

if received prior to the date and time for appearance.

Failure to comply with the requirements of this subpoena will render you liable to proceedings in the district court of the United States to enforce obedience to the requirements of this subpoena, and to punish default or disobedience.

Issued under authority of Sec. 248 of the Health Insurance Portability & Accountability Act of 1996, Public Law No. 104-91 (18 U.S.C. § 3486)

IN TESTIMONY WHEREOF

[redacted]
Health Care Fraud Chief, USAO Massachusetts
the undersigned official of the U.S. DEPARTMENT OF JUSTICE, has hereunto set her hand this b6 b7C
27th d[redacted]
(SIGNATURE)

FORM CRM-180
MAR. 97

b6 b7C

209A-BS-92295-SOP-[redacted]

RETURN OF SERVICE

I, being a person over 18 years of age, hereby certify that a copy of this subpoena was duly served on the person named herein by means of --

1. personal delivery to an individual, to wit:

[redacted]

(Address)

Hard copy sent by U.S. mail to [redacted]

2. personal delivery to an address,

(Description of premises)

(Address)

3. registered or certified mailing to:

(Name)

Address)

at 4:40( ) a.m. (✓) p.m. on 10/30/2006

[redacted]

Special Agent - FBI - Boston, MA.

(Title)

UNITED STATES OF AMERICA
DEPARTMENT OF JUSTICE

b6
b7C

SUBPOENA DUCES TECUM

Upon contumacy or refusal to obey, this subpoena shall be enforceable by order of the appropriate United States District Court.

b6
b7C

FD-448
Revised
10-27-2004

FEDERAL BUREAU OF INVESTIGATION
FACSIMILE COVER SHEET

PRECEDENCE

○ Immediate ○ Priority ◉ Routine

CLASSIFICATION

○ Top Secret ○ Secret ○ Confidential ○ Sensitive ◉ Unclassified

TO

Name of Office: [redacted]
Facsimile Number: [redacted]
Date: **10/30/2006**
Attn: [redacted]
Room:
Telephone Number: [redacted]

b6
b7C
b7E

FROM

Name of Office: **FBI - Boston, MA**
Number of Pages: (including cover) **6**
Originator's Name: [redacted]
Originator's Telephone Number: [redacted]
Originator's Facsimile Number: [redacted]
Approved:

b6
b7C
b7E

DETAILS

Subject:
Health Insurance Portability & Accountability Actt Subpoena

Special Handling Instructions:
If you have any questions please call AUSA [redacted]

b6
b7C

Brief Description of Communication Faxed:
HIPAA subpoena for records. Deadline: 11/28/2006. Copy will also be forwarded by U.S. Mail to:
[redacted]

b6
b7C

WARNING

Information attached to the cover sheet is U.S. Government Property. If you are not the intended recipient of this information disclosure, reproduction, distribution, or use of this information is prohibited (18.USC, § 641). Please notify the originator or local FBI Office immediately to arrange for proper disposition.

Page 85 ~ b5; b6; b7C; b7E;
Page 86 ~ b5; b6; b7C; b7E;
Page 88 ~ b5; b6; b7C; b7E;
Page 89 ~ b5; b6; b7C; b7E;
Page 90 ~ b5; b6; b7C; b7E;
Page 91 ~ b5; b6; b7C; b7E;
Page 92 ~ b5; b6; b7C; b7E;
Page 93 ~ b5; b6; b7C; b7E;
Page 94 ~ b5; b6; b7C; b7E;
Page 95 ~ b5; b6; b7C; b7E;
Page 96 ~ b5; b6; b7C; b7E;
Page 97 ~ b5; b6; b7C; b7E;
Page 98 ~ b5; b6; b7C; b7E;
Page 101 ~ b6; b7C; b7E;
Page 102 ~ b6; b7C; b7E;
Page 103 ~ b6; b7C; b7E;

XXXXXXXXXXXXXXXXXXXXXXXXX
X Deleted Page(s) X
X No Duplication Fee X
X For this Page X
XXXXXXXXXXXXXXXXXXXXXXXXX

AO 110 (Rev. 5/85) Subpoena to Testify Before Grand Jury

United States District Court

DISTRICT OF MARYLAND

TO: [redacted]

b3
b6
b7C

SUBPOENA TO TESTIFY BEFORE GRAND JURY

SUBPOENA FOR: [redacted] b3

YOU ARE HEREBY COMMANDED to appear and testify before the Grand Jury of the United States District Court at the place, date, and time specified below.

PLACE	COURTROOM
United States Courthouse Suite 400 6500 Cherrywood Lane Greenbelt, Maryland 20770	400 [redacted] b3

YOU ARE ALSO COMMANDED to bring with you the following document(s) or object(s):*

[redacted] b3

SEARCHED [redacted] INDEXED [redacted]
SERIALIZED [redacted] FILED [redacted]
NOV 0 : 199
FBI — BALTIMO

b6
b7C

☐ *Please see additional information on reverse*

This subpoena shall remain in effect until you are granted leave to depart by the court or by ... behalf of the court.

209B BA-87450
Sub SBP-19

CLERK	DATE
JOSEPH A. HAAS	September 26, 1995

[redacted]

This subpoena is issued on application of the United States of America

LYNNE A. BATTAGLIA

NAME, ADDRESS AND PHONE NUMBER OF ASSISTANT U.S. ATTORNEY

AUSA [redacted]
U.S. Courthouse, Suite 400
6500 Cherrywood Lane

b6
b7C

b6
b7C

OO: NEWARK
NK 92A-6135

b7D

furnished the following information on December 2 and 5, 1988:

SALVATORE "TUTTI" LOMBARDINO's mother-in-law, LUCILLE ANASTISIA, died during the past week. Her funeral was held at MC CRACKEN'S FUNERAL HOME in Union, New Jersey.

b6
b7C
b7D

the SANDOZ COMPANY in East Hanover, New Jersey.

b6
b7C
b7D

b6
b7C

92A-6135-351

FEDERAL BUREAU OF INVESTIGATION
FOI/PA
DELETED PAGE INFORMATION SHEET
FOI/PA# 1468056-000

Total Deleted Page(s) = 1
Page 2 ~ Duplicate;

XXXXXXXXXXXXXXXXXXXXXXXX
X Deleted Page(s) X
X No Duplication Fee X
X For this Page X
XXXXXXXXXXXXXXXXXXXXXXXX

[redacted]

b6
b7C

OCIS

[redacted]

b6
b7C

RE1;
92A-6137

[redacted] advised Special Agent (SA) [redacted] and SA [redacted] of the following information:

b6
b7C
b7D

[redacted]

is working at SANDOZ PHARMACEUTICALS located on the corner of Ridgedale and Route 10, Whippany, New Jersey.

b6
b7C
b7D

[redacted]

NK 92A-6137-1094

SEARCHED ____ INDEXED ____
SERIALIZED ____ FILED ____

FEB 19 1993

FBI — NEWARK

b6
b7C

OCIS

FEDERAL BUREAU OF INVESTIGATION
FOI/PA
DELETED PAGE INFORMATION SHEET
FOI/PA# 1468056-000

Total Deleted Page(s) = 1
Page 2 ~ Duplicate;

XXXXXXXXXXXXXXXXXXXXXXXX
X Deleted Page(s) X
X No Duplication Fee X
X For this Page X
XXXXXXXXXXXXXXXXXXXXXXXX

April 25, 1979

[redacted]

b6
b7C

[redacted]

OUTSIDE SOURCE

Sandoz Pharmaceuticals
Suite 1101
1050 17th Street, N.W.
Washington, D. C. 20036

Dear [redacted]

b6
b7C

Thank you for your very thoughtful letter of April 11th. It was a privilege to appear at the RAMS luncheon and it is encouraging to me to know the FBI and I have your support and confidence.

I would enjoy meeting with you [redacted] at some time in the future and I would suggest you contact my secretary, [redacted] at telephone number [redacted] when you have a definite date in mind. My schedule is extremely busy; however, I will make every effort to see you if at all possible.

b6
b7C

With every best wish,

Sincerely yours,

William H. Webster

William H. Webster
Director

MAILED 8
APR 26 1979
FBI

V-1

DE-44

REC-2

94-6946-4

6 APR 30 1979

1 - [redacted] - Enclosure
1 - [redacted] - Enclosure
1 - Telephone Room - Enclosure

b6
b7C

Assoc. Dir.
Dep. AD Adm.
Dep. AD Inv.
Asst. Dir.:
Adm. Servs.
Crim. Inv.
Ident.
Intell.
Laboratory
Legal Coun.
Plan. & Insp.
Rec. Mgmt.
Tech. Servs.
Training
Public Affs. Off.
Telephone Rm.
Director's Sec'y

NOTE: The Director made remarks before a meeting of the Republicans Associated for Mutual Support (RAMS) in Washington, D. C., on 4-5-79. Bufiles contain no record of correspondent. [redacted] is a former SA who EOD [redacted]

APPROVED:
Adm. Serv.
Legal Coun.
Plan. & Insp.
Rec. Mgmt.
Tech. Servs.
Training
Public Affs. Off.

MAIL ROOM

b6
b7C

FEDERAL BUREAU OF INVESTIGATION
FOI/PA
DELETED PAGE INFORMATION SHEET
FOI/PA# 1468056-000

Total Deleted Page(s) = 8
Page 14 ~ b6; b7C;
Page 15 ~ b6; b7C;
Page 16 ~ b6; b7C;
Page 17 ~ b6; b7C;
Page 20 ~ b6; b7C;
Page 21 ~ b6; b7C;
Page 22 ~ b6; b7C;
Page 23 ~ b6; b7C;

XXXXXXXXXXXXXXXXXXXXXXXX
X Deleted Page(s) X
X No Duplication Fee X
X For this Page X
XXXXXXXXXXXXXXXXXXXXXXXX

Memorandum

To : ACTING SAC, NEWARK (15B-51082) (C) Date 4/25/89

From : SA [redacted] (PARA)

b6
b7C

Subject: UNSUB;
THEFT OF TWO SHIPMENTS OF
SANDOZ PHARMECUTICALS FROM
SANDOZ CORP. AT EAST
HANOVER, NEW JERSEY,
6/22/88 - 7/19/88;
TFIS;
OO: NEWARK

DUPLICATE SERIALS PURGED
AND DES... HEADQUARTERS
DATED 11/2/86, CH 4/28/89 INITIALS

As all investigation has been conducted with negative results and no subjects have been developed, it is recommended that this case be closed administratively at this time.

It should be noted that the stolen property is not identifiable if recovered and that there was over one month delay in reporting this matter to the FBI from the time of theft.

b6
b7C

[redacted]

b6
b7C

[redacted]

15B-51082-2

Alpha
Origin
Supv
Supv
Priority
Date
Squad

Complaint Form
FD-71 (Rev. 2-13-86)

NOTE: Hand print names legibly; handwriting satisfactory for remainder.
Indices: ☐ Negative ☐ See below

Subject's name and aliases	Character of case
UNSUB Theft of two shipments of SANDOZ PHARMACEUTICALS SANDOZ CORPORATION EAST HANOVER, NJ	TFIS
	Complainant ☐ Protect Source [redacted]
	Complaint received ☑ Personal ☐ Telephonic Date 8-24-88 Time
Address of subject 6/22 - 7/19/88 TFIS OONE	Complainant's address and telephone number SANDOZ PHARMACEUTICALS CORP. EAST HANOVER, NJ

Subject's Description						
Race	Sex ☐ Male ☐ Female	Height	Hair	Build	Birth date and birthplace	
Age		Weight	Eyes	Complexion	Social Security Number	
Scars, marks or other data						

Facts of complaint

Complainant advised that there has been two thefts of SANDIMMUNE (heart transplant medicine) from the SANDOZ Corp. EAST HANOVER N.J. in the last two months. The following is the DATA on above two thefts

Shipment 1 SANDOZ Corp. EAST HANOVER N.J. to [redacted] (3 CTN shipment arrived 2 CTN short) Date of shipment 6-22-88 Value of loss $40,000

Shipment 2 SANDOZ Corp. EAST HANOVER N.J. to [redacted] (3 CTN shipment one of the CTNS arrived) Date of shipment 7-19-88 Value of loss $60,000

Complainant advised all shipments were transported via [redacted]

OTA

BLOCK STAMP

b6
b7C

FD-340a (Rev. 10-3-77)

(Title) _____

(File No.) NF. 15B-51082-1A.

Item	Date Filed	To be returned Yes	No		Disposition
1.	4/20/89			ORIG INT NOTES OF [redacted] FROM AGENT. REC'D 10/7/88. BY [redacted]	b6 b7C
2.	4/20/89			COPIES OF SHIPPING BILLS ON STOLEN PHARMACEUTICALS. FROM [redacted] SANDOZ CORP. E HANOVER, NJ. REC'D 10/14/88. BY [redacted]	b6 b7C

b6
b7C

APR 20 1989

FBI — NEW

15B-51082-1A

FD-340b (Rev. 4-2-85)

Field File No. 158 51082-1A1

Serial # of Originating Document

00 and File No.

Date Received 01/7/88

From

(NAME OF CONTRIBUTOR)

(ADDRESS OF CONTRIBUTOR)

By [redacted] b6 b7C

To Be Returned ☐ Yes ☒ No Receipt Given ☐ Yes ☒ No

Grand Jury Material - Disseminate Only Pursuant to Rule 6(e), Federal Rules of Criminal Procedure
☐ Yes ☐ No

Title:

Reference:

(Communication Enclosing Material)

Description: ☒ Original notes re interview of

[redacted] b6 b7C

10/7/88

[redacted] b6 b7C

[redacted] b6 b7C

6/20/88

3 carton shipment -

from Sandoz & Corp.

Cedar Hanover N.J.

R. [redacted] b6 b7C

3 cartons [redacted] b6 b7C

2 carton short -

Anti organ Rejection Drug

Liquid -

50 ml per bottle

3 cartons (certified) 400 50 ml bottles - sprocket 100 Micrograms

Net wgt 148 lbs for

Gross wgt 162.80

$62,880.00 for the 3 cartons

- Missing carton's -

1 carton or 120 bottles was valid.

2 cartons of 280 bottles were

missing $44,016.00 value

Taken orally.
Did not sign bottles or shower bottle he would fill enclosed prescription from it.
Lot # Quality # 259407614
Not uniquely identified identifiers
Numerous bottles with the same lot. No
Sold only by prescription

6/22/88
3:40PM

b6
b7C

[redacted]

b6
b7C

[redacted]

[redacted] is one of the more expensive drugs that we ship.

6/30/88 - [redacted] also informed us that they only resell 1 case.

b6
b7C

140
-3/1000
3/10

7/19/88 SUMMARY - 9

TO [redacted] b6 b7C

[redacted]

920 BOTTLES 50ML - 100 MILLIGRAMS
[redacted] excess of how many bottles
per case -
Quality control # 266L07618
LOT #
Not uniquely identifiable:
VALUE -
SANDOZ out PRICE -
$66,024.00

[redacted] b6 b7C

LOT # CONTROLLED SUBSTANCE

FD-340b (Rev. 4-2-85)

Field File No. 15-B 51082-1A2

Serial # of Originating Document

00 and File No.

Date Received 10/14/88

From [redacted]
(NAME OF CONTRIBUTOR)

Sandoz Corp
(ADDRESS OF CONTRIBUTOR)

East Hanover, N.J.

By [redacted]

To Be Returned ☐ Yes ☒ No Receipt Given ☐ Yes ☒ No

Grand Jury Material - Disseminate Only Pursuant to Rule 6(e), Federal Rules of Criminal Procedure
☐ Yes ☐ No

Title:

Reference:
(Communication Enclosing Material)

Description: ☐ Original notes re interview of

Copies of shipping bills on stolen pharmaceuticals

b6
b7C

SANDOZ

Sandoz Corporation
608 Fifth Avenue
New York, New York 10020
212.307.1122

~~CONFIDENTIAL~~

October 7, 1988

F.B.I.
P.O. Box 64
Parsippany, NJ 07054

Attn: Special Agent [redacted] b6 b7C

Gentlemen:

Enclosed is the information we discussed in our telephone conversation of Friday, October 7, 1988. I will check further on the [illegible]s.

Very truly [illegible]

SA[illegible]

[redacted] b6 b7C

Attachment
88467

S

Check QA #
Check lot #
same

CONSIGNEE [redacted]

b6
b7C

[redacted]

INVOICE NO [redacted]
INVOICE DATE
PACKING NO

ITEM DESCRIPTION 50mL SANDIMMUNE 100mg
AMT ORDERED 420
AMT RECEIVED 0
SHORTAGE 420
TOTAL INVOICE VALUE 66034.00
SHORTAGE VALUE 66034.00
SHIP DATE 7/19/88
PROBLEM REPORTED 7/26/88
POD 7/26/88 CALLED [redacted] SHOWS LOST

b6
b7C

7/26/88 [redacted] CALLED [redacted] CONTACT?
7/27/88 CALLED [redacted] SYSTEM CK - STILL LOST
7/28/88 CA. CALLED FOR MORE INFO ON SHIPMENT DESCRIPTION ETC. CONTACT [redacted]

b6
b7C

7/29/88 [redacted] STILL SHOWS LOST.
8/15 [redacted] CALLED FOR INFO

CONT

OH & LOST SHIPS ASK who should he
CONTACT AT SANDOZ GAVE [redacted]
NAME

8/15 CALLED [redacted] - STILL LOST

8/15 CALLED [redacted]

8/15 CALLED [redacted]

PORTLAND WILL CK FROM HIS END.

8/16 [redacted] CALLED ORDER STILL LOST

8/16 CLAIM being PLACED

8/16 INSURANCE CLAIM PLACED.

b6
b7C

b6
b7C

b6
b7C

[redacted]

CONSIGNEE [redacted]

b6
b7C

[redacted]

INVOICE NO [redacted]
INVOICE DATE
PACKING NO

ITEM DESCRIPTION 50mL SARIDIMNIVINE 100mg
AMT ORDERED 400
AMT RECEIVED 120 (1 Box)
SHORTAGE 280 (2 Boxes)
TOTAL INVOICE VALUE 62,880.00
SHORTAGE VALUE 44016.00
SHIP DATE 6/22/88
PROBLEM REPORTED 6/30/88
POD 6/30/88 by [redacted]
INFO ASKED FOR ON 7/6 by [redacted] REPORTED
LOST AFTER A ALL SYSTEM'S OK.
RECALLED 7/7 STILL LOST
CLAIM FILED 7/11
INSURANCE DEPT 7/11
CALLED [redacted] 8/15/88 INFORMED
THAT SHIPMENT WAS STILL LOST CANNOT FIND ALSO TALKED
WITH [redacted]

b6
b7C

b6
b7C

b6
b7C

CONT

b6
b7C

CALLED [redacted] SECURITY IN PORTLAND 8/15/88 GAVE HIM ALL INFO WILL CK OUT FROM HIS END.

PARA CASE
PLS CALL SA

OPEN OR REOPEN
ALPHA B
ORIGIN NY
SUPV. [redacted]
DATE 8-20
SOURCE I P A

15B-51082-1
FOI
SEARCH
SERIALIZ
1988
FBI - NEWARK

b6
b7C

FEDERAL BUREAU OF INVESTIGATION
FOI/PA
DELETED PAGE INFORMATION SHEET
FOI/PA# 1468056-000

Total Deleted Page(s) = 11
Page 8 ~ b6; b7C;
Page 9 ~ b6; b7C;
Page 16 ~ Duplicate;
Page 17 ~ Duplicate;
Page 18 ~ Duplicate;
Page 21 ~ Duplicate;
Page 25 ~ Duplicate;
Page 26 ~ Duplicate;
Page 27 ~ Duplicate;
Page 31 ~ Duplicate;
Page 32 ~ Duplicate;

XXXXXXXXXXXXXXXXXXXXXXXX
X Deleted Page(s) X
X No Duplication Fee X
X For this Page X
XXXXXXXXXXXXXXXXXXXXXXXX

Memorandum

To : ACTING SAC, NEWARK (15B-NK-63372) (C) Date 10/17/89

From : SA [redacted] b6 b7C

Subject: UNSUBS;
THEFT OF 280, 50 ML BOTTLES OF SANDINMUNE DRUG
VALUED IN EXCESS OF $50,000;
EAST HANOVER, NJ;
TFIS;
OO: NK

On 2/23/89, SANDOZ PHARMACEUTICALS CORPORATION, 59 Route 10, East Hanover, New Jersey, shipped 360 50 ml, bottle of Sandinmune drug to [redacted] b6 b7C

[redacted] is the contracted shipper for SANDOZ PHARMACEUTICALS and they used [redacted] to pick up the SANDOZ shipment at there East Hanover plant. On 3/3/89, SANDOZ PHARMACEUTICAL received notice that 280 bottles of the Sandinmune drug had not arrived. The value of the missing shipment is valued in excess of $50,000. b6 b7C

Investigation revealed that [redacted] to move the shipment from the SANDOZ PLANT to the [redacted] warehouse. The shipment is then shipped to a consolidation hub, located in Indianapolis, where it once again is consolidated and shipped onto the consignees location. b6 b7C

[redacted] only verifies the shipment as being intact when it arrives at the shipping terminal and when it arrives at the destination terminal. b6 b7C

Authorities at [redacted] state that there is no way of verifying the shipment's intact during the shipping process and the shipment changes containers during this process as well. Investigation has failed to develop any positive suspects and no additional information has been obtained to further this investigation.

It is requested that this case be closed administratively.

[redacted] 15B-NK-63372-6

[redacted] Newark

[redacted] (1) 1*

DUPLICATE SERIALS PURGED
AND [redacted] PUAIRTEL [redacted] b6
DATED 11/3/89, ON 10/25/89 INITIA b7C

Indices Search Slip
FD-180 (Rev. 7-21-83)

TO: OFFICE SERVICES MANAGER

Date: 7 JUNE 89

Subject: SANDOZ PHARM. CORP.

Social Security Account #:

Aliases:

Address	Birth Date	Birthplace	Race	Sex ☐ Male ☐ Female

☐ Exact Spelling
☐ All References
☐ Main Security Case Files Only
☐ Security References Only
☐ Main Criminal Case Files Only
☐ Criminal References Only
☐ Main Security (If no Main, list all Security References)
☐ Main Criminal (If no Main, list all Criminal References)
☐ Restrict Locality of

File & Serial Number	Remarks	File & Serial Number	Remarks
FOIMS			
183A-1643-1D-49507	SANDOZ WANDED INC.		
	DATE & ADDRESS	POSITIVE	

Requested by | Squad | Extension | File No.

☐ General Indices: FOIMS [redacted] L.G. 6-7-89
Searched by | Date

☐ Confidential Indices:
Searched by | Date

☐ ELSUR Indices:
Searched by | Date

☐ ISIS:
Searched by | Date

☐ OCIS:
Searched by | Date

☐ Elt:
Searched by | Date

b6
b7C

Consolidated by | Date

Reviewed by | Date

File Review Symbols
I - Identical
NI - Not identical
? - Not identifiable
U - Unavailable reference

Indices Search Slip
FD-160 (Rev. 7-21-83)

TO: OFFICE SERVICES MANAGER

Date: 9 JUN 89

Subject:

Social Security Account #:

Aliases:

b6
b7C

Address	Birth Date	Birthplace	Race	Sex ☐ Male ☐ Female

☐ Exact Spelling
☐ All References
☐ Main Security Case Files Only
☐ Security References Only
☐ Main Criminal Case Files Only
☐ Criminal References Only
☐ Main Security (If no Main, list all Security References)
☐ Main Criminal (If no Main, list all Criminal References)
☐ Restrict Locality of

File & Serial Number	Remarks	File & Serial Number	Remarks
FOIMS-			
1838-2309-2-258			

Requested by

Squad | Extension | File No.

☐ General Indices: FOIMS [redacted] L-G 6-9-89
Searched by | Date

☐ Confidential Indices:
Searched by | Date

☐ ELSUR Indices:
Searched by | Date

☐ BIS:
Searched by | Date

☐ OCIS:
Searched by | Date

☐ SII:
Searched by | Date

b6
b7C

Consolidated by | Date

Reviewed by | Date

File Review Symbols
! - Identical
? - Not Identifiable
NI - Not Identical
U - Unavailable reference

FD-340a (Rev. 10-3-77)

(Title) 15B-NK-63372-1A

(File No.)

Item	Date Filed	To be returned Yes	To be returned No		Disposition
1	1/2/90		MK	CONSIGNEE CARRIER COMPANYS NAMES AND ADDRESSES. REC: BY:	

15B-NK-63372-1A

SEARCHED SERIALIZED FILED FOIMS EXED

07 1990

FBI — NEWARK

b6
b7C

FD-340 (Rev. 4-2-85)

b6
b7C

Field File No. 15B-NK-63372-1A1

Serial # of Originating Document _____

OO and File No. NK

Date Received _____

From SANDOZ PHARMACEUTICAL
(Name of Contributor)

_____
(Address of Contributor)

_____
(City and State)

By _____
(Name of Special Agent)

To Be Returned ☐ Yes ☐ No Receipt Given ☒ Yes ☐ No

Grand Jury Material - Disseminate Only Pursuant to Rule 6(e), Federal Rules of Criminal Procedure ☐ Yes ☐ No

Title: UNSUBS; Theft of Sandoz Pharmaceutical

Reference: _____
(Communication Enclosing Material)

Description: ☐ Original notes re interview of

Consignee Carrier Companys names and addresses

Sandoz Pharmaceuticals Corporation
SANDOZPHARMACEUTICALS
Route 10
East Hanover, New Jersey 07936

EAST HANOVER
JUL 10 89
N.J.

US POSTAGE
$0.25
METER
010888

b6
b7C

Federal Bureau of Investigation

Gateway 1, Market Street

Newark, NJ 07102

15B-NK-62372-2

b6
b7C

SEARCHED
SERIALIZED
INDEXED

JUN 19 1989

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 6/13/89

[redacted] of b6 b7C
SANDOZ PHARMACEUTICALS, CORPORATION, Route 10, East Hanover, New Jersey, 07936, telephone number (201) 503-7701, were contacted at their places of employment where they were advised of the identity of the interviewing agent and the nature of the interview, they thereafter provided the following information:

SANDOZ is a pharmaceutical drug manufacturer based in Basle, Switzerland, which imports the drug to the United States for distribution. SANDOZ, CORPORATION, which is the base of operations in the United State, is headquartered in New York, and SANDOZ PHARMACEUTICALS, CORPORATION is the base of distribution for the United States, located at 59 Route 10, East Hanover, New Jersey.

SANDOZ PHARMACEUTICALS, CORPORATION (SPC) received the drug from the manufacturing plant in Switzerland which has labeled and packaged the drug. Once at the distribution facility, the drug is either distributed to the customers in the original shipping boxes or separated into smaller quantities.

[redacted] noted that SANDOZ manufactures two types of b6 b7C
drugs; sandinmune and sandoglobilin and both drugs are distributed through SPC in the United States but the only thefts have been from the sandinmune drug shipments.

SPC is the sole distributor of SANDOZ drugs throughout the United States and distributes drugs to drug wholesalers, (there are approximately 350 of these customers) and hospitals (there are thousands of hospitals that they ship to directly). SPC does not sell the drug to the retail sales market since the drugs are used by hospitals for organ transplants. [redacted] b6 b7C
explains that the drugs are used for the reduction of a human body immune system allowing for an organ transplant to be successful.

[redacted] states that the drugs are not a narcotic type drug and the drug cannot be used in combination with other drugs for any purpose.

Investigation on 5/31/89 at East Hanover, New Jersey File # NK 15B-NK-63372

by SA [redacted] Date dictated 6/5/89 b6 b7C

This document contains neither recommendations nor conclusions of the FBI. It is the property of the FBI and is loaned to your agency; it and its contents are not to be distributed outside your agency.

b6
b7C

SPC uses several trucking companys for shipping their product. [redacted] has been shipping for SPC for approximately three years. [redacted] for trucking SPC products to [redacted] then the product is flown out of NEWARK INTERNATIONAL AIRPORT the following day to consignee's location.

b6
b7C

[redacted] stated that SPC does not have a record of what trucking company trucked this product from the arriving airport to the cosignee's location, but he is attempting to locate that information for this investigation.

b6
b7C

[redacted]

b6
b7C

[redacted] stated that on August 15, 1988, SPC notified [redacted] of the losses of their product during shipping by [redacted] initiated an investigation into the losses but he could not provide the results of their investigation at this time.

b6
b7C

[redacted] stated that during the period of June 22, 1988 through February 23, 1989, SPC has lost in transport the sandinmune drug intended for cosignee.

b6
b7C

[redacted] provided the following:

[redacted]

b6
b7C

b6
b7C

[redacted]

b6
b7C

[redacted] stated that SPC can identify any product of theirs by the lot number and provide when the shipment was distributed, should any of the missing sandinmune be located.

b6
b7C

[redacted] advised that [redacted] has been canceled as a carrier of their product and since that time no further losses have occurred.

b6
b7C

15B-NK-63372-3

SEARCHED [redacted] INDEXED
SERIALIZED [redacted] FILED

JUN 1 9 1989

NEWARK

b6
b7C

FD-302 (REV. 3-10-82)

FEDERAL BUREAU OF INVESTIGATION

1

Date of transcription 6/12/89

[redacted] was contacted at his place of employment, where he was advised of the identity of the interviewing agent and the nature of the interview. He thereafter provided the following information: b6 b7C

SANDOZ PHARMACEUTICALS CORPORATION (SPC), 59 Route 10, East Hanover, New Jersey, has retained the services of [redacted] the purpose of providing advise to SPC concerning numerous thefts that have occurred during the period June 22, 1988, through February 23, 1989. b6 b7C

[redacted] stated that SPC is the sole United States distributor of a drug used in the medical industry for transportation of human organs. The two major drugs distributed are named Sandinmune and Sandoglobilin. b6 b7C

SPC received the drugs from the Switzerland manufacturer which they then distribute to customers in the United States.

[redacted] states that SPC utilizes [redacted] as the trucking firm and the air carrier for distribution of the drug. [redacted] will pick up the shipment at SPC and deliver the shipment to their warehouse at 225 North Avenue, Elizabeth, New Jersey, where the shipment will be airfreighted out to the consignee, no later then the following day. b6 b7C

During the period of June 22, 1988 - February 23, 1989, SPC has distributed numerous shipments of the Sandinmune drug to consignees throughout the United States by use of [redacted] where shipments have either been delivered short or not delivered at all. The value of the thefts amount from $44,016.00 to $69,000.00 b6 b7C

Investigation on 5/30/89 at Summit, New Jersey File # NK 15B-NK-63372

by SA [redacted] Date dictated 5/31/89 b6 b7C

This document contains neither recommendations nor conclusions of the FBI. It is the property of the FBI and is loaned to your agency; it and its contents are not to be distributed outside your agency.

185-NK-62372-4

SEARCHED INDEXED

SERIALIZED

SEP 0 6 1989

FBI - NEWARK

b6
b7C

FD-302 (REV. 3-10-82)

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 7/3/89

[redacted] was telephonically contacted at his place of employment, where he was advised of the identity of the interviewing agent and the nature of the interview, he thereafter provided the following information. b6 b7C

[redacted] had been handling the shipping of SANDOZ PHARMACEUTICALS throughout the United States, when [redacted] for SANDOZ, notified the Newark Terminal of [redacted] that shipments of their product were being stolen during transport. The Newark Terminal supervisor notified their security office, informing them of the losses being claimed by SANDOZ PHARMACEUTICAL. b6 b7C

[redacted] stated that an investigation was initiated by their department and they attempted to locate the cause of the thefts and any suspects, but their investigation failed to develop any positive information into this matter. b6 b7C

He stated that [redacted] handles their shipments in such a way that it makes it difficult for any package to be traced as it travels throughout the system. [redacted] stated that once a package is picked up at the original shippers location, the package is checked to confirm that it corresponds with the shipping manifest that the driver is picking up and transported to the Newark Terminal. At the terminal, the package is then placed into an "A Container" and is labeled with a computer generated number, where it is stored until it is shipped by either aircraft or truck later that night, destined to the consolidation "Hub", located in Indianapolis, Indiana. He states that the package can not be traced from that point on, because so many different people handle the package during its transport. b6 b7C

[redacted] stated that the next opportunity to confirm that the package is still completely intact, is when it arrives at the destination terminal, where a contracted trucking company would pick up the package and confirm that the package corresponds with the paperwork that was sent by the shipping terminal. b6 b7C

Investigation on 7/3/89 at Newark, New Jersey File # 15B-NK-63372

by SA [redacted] Date dictated 7/3/89 b6 b7C

This document contains neither recommendations nor conclusions of the FBI. It is the property of the FBI and is loaned to your agency; it and its contents are not to be distributed outside your agency

 b6 b7C

He states that when the losses of the SANDOZ shipments were reported, [redacted] attempted to institute a "signature" check system that would have the signature of all persons that came into contact with the package on a paper trail to follow, but the system was not successful due to the way the [redacted] system operates. b6 b7C

[redacted] states that during their investigation, the security department placed several undercover investigators in the consolidation "Hub" to determine if they could locate any evidence of thefts, but due to the size of the "Hub", which is approximately three footballs lengths long, they were unable to develop any suspects. b6 b7C

[redacted] stated that they attempted to locate any of the SANDOZ product at other destination terminals, believing that the package may have inadvertently been miss routed, but they were not able to find any evidence of the package arriving at other terminals nor did they find that they were able to locate any evidence of SANDOZ products being stolen by their employees of [redacted] b6 b7C

15B-NK-63372-5

SEARCHED
SERIALIZED
SEP 08 1989

b6
b7C

FD-302 (Rev. 3-10-82)

FEDERAL BUREAU OF INVESTIGATION

Date of transcription 7/6/89

[redacted] was contacted at his place of employment where he was advised of the identity of the interviewing agent and the nature of the interview. He thereafter provided the following information: b6 b7C

[redacted] b6 b7C

[redacted] explained that [redacted] is a nationwide airfreight company that handles overnight and second day package delivery service. In the case of SANDOZ PHARMACEUTICAL, INCORPORATED, [redacted] picks up shipments at the SANDOZ PHARMACEUTICAL, INCORPORATED, warehouse on Route 59, East Hanover, NJ, and the driver signs the trucking manifest for the shipment. The [redacted] then transports [redacted] Upon the shipment's arrival at the warehouse, the shipment is off loaded and stored in a holding area. At the warehouse, the shipment is labeled with a computer generated order number and then loaded into an "A" container for shipping. The shipment will leave the warehouse no later than 11:00 P.M. that day. b6 b7C

b6 b7C [redacted] explained that [redacted] would then either truck the shipment or fly the shipment to the shipment consolidation "HUB" located in Indianapolis, Indiana, where the shipment is off loaded, sorted and placed into another "A" container according to the shipment's final destination. The shipment is then either trucked or flown once again to the [redacted] terminal closest to the consignee's location where a local trucking company would then pick up the shipment, check to confirm that the shipment is correct according to the computer general delivery receipt. [redacted] stated that there are only two points in the operation where the shipment is counted to confirm that it corresponds with the shipping

Investigation on 7/3/89 at Newark, New Jersey File # Newark 15B-NK-63372

by SA [redacted] Date dictated 7/6/89 b6 b7C

This document contains neither recommendations nor conclusions of the FBI. It is the property of the FBI and is loaned to your agency; it and its contents are not to be distributed outside your agency.

b6
b7C

manifest and they are one, at the point where the [redacted] Driver picks up the shipment at the shipper's warehouse and two, at the destination terminal where the local trucking company driver picks up the shipment for delivery.

[redacted] stated that [redacted] handles over two million pieces of shipment per day, therefore, they cannot count each piece.

b6
b7C

He stated that when a shipment is trucked to the Indianapolis "HUB", [redacted] handles all the trucked shipments. In the case of the trucking company, when a shipment leaves the warehouse, a rear door seal is attached to the rear doors and the seal number is recorded in the computer, the shipping manifest record and the seal is verified as intact upon it's arrival at the "HUB".

b6
b7C

[redacted] does not have a "hard copy" delivery bill accompany the shipment when it moves to the "HUB" and then onto destination terminal. The paperwork is generated at the shipping terminal, created by the [redacted]

b6
b7C

[redacted] explained that if an order arrives at the [redacted] warehouse incomplete, [redacted] would notify SANDOZ PHARMACEUTICAL and inform them of the discrepancy where they would store the shipment until the complete shipment could be sent out.

b6
b7C

In the case of shipment not arriving at the destination terminal, the Platform Supervisor would notify the "HUB" as well as the original shipping terminal [redacted] would proceed to check other points where the shipment may have been mis-routed. In cases where entire shipments were lost in transit, notification would be made to the Security and Loss Prevention Control.

b6
b7C

[redacted] states that in the case of SANDOZ PHARMACEUTICAL, INC., losses, [redacted] was notified and an investigation was initiated by their department.

b6
b7C

He states that to his knowledge, no products were ever located nor any suspects identified.

UNITED STATES GOVERNMENT

memorandum

DATE: 6/1/89

REPLY TO ATTN OF: SA [redacted] b6 b7C

SUBJECT: UNSUBS;
THEFT OF 280, 50 ML BOTTLES OF
"SANDINMUNE" DRUG;
VALUED IN EXCESS OF $50,000.00,
EAST HANOVER, NEW JERSEY;
TFIS
OO: NEWARK

TO: SAC, NEWARK (15B-NK-)(P) (C-2)

On 2/23/89, SANDOZ PHARMACEUTICALS CORPORATION, 59 Route 10, East Hanover, New Jersey, shipped 360 50 ML, bottle of "Sandinmune" drug to [redacted] b6 b7C

The shipment was trucked by [redacted] to NEWARK INTERNATIONAL AIRPORT where the shipment was warehoused and flown to MIAMI INTERNATIONAL AIRPORT by [redacted] the following day. Upon its arrival at MIAMI INTERNATIONAL AIRPORT the shipment was delivered to the [redacted] b6 b7C

On 3/3/89, SANDOZ PHARMACEUTICAL received notice that 280 bottles of the "Sandinmune" drug, valued in excess of $50,000.00 was missing from the shipment.

This matter is requested to be opened and assigned to SA [redacted] b6 b7C

15B-NK-63372-1

2-Newark
(2) [redacted]

OPEN OR REOPEN CASE ..... 1$
ALPHA ..... B ..... PRIORITY ....I....II....III...
ORIGIN ..... NK ..... PI INST. .....
SUPV. ..... [redacted] ..... PI EXPIRES .....
DATE ..... 6-7-89 ..... POI* ..... *
SOURCE I P A CY CT

SEARCHED INDEXED
SERIALIZED FILED
JUN 01 1989
FBI - NEWARK

b6 b7C

OPTIONAL FORM NO. 10
(REV. 1-80)
GSA FPMR (41 CFR) 101-11.6
5010-114
☆GPO : 1985 O - 461-275 (413)